Do we need SBRT doses > 130Gy BED in early stage NSCLC? Uncertainties such as dose calculation algorithm, dose prescription, volume effect, SBRT accuracy ... remain unconsidered in this analysis. Prospective evidence needed. https://t.co/5GlPJK3UDF
Effectiveness and safety of “real” concurrent stereotactic radiotherapy and immunotherapy in metastatic solid tumors: a systematic review https://t.co/89Yko0nUGX
SABR for oligometastatic bone only breast cancer is safe, feasible and convenient with excellent local control. Majority of patients do not progress at 2 years and remained alive without further systemic treatment https://t.co/sldR9IYUzR
El 40% de los cánceres se curan gracias a la #radioterapia, bien como tratamiento único o asociado a cirugía o quimioterapia. ¿No lo sabías? Pregunta un oncólogo, pero uno experto en radioterapia: un oncólogo radioterápico.
Finally! A randomised trial of upfront SABR in #lungcancer patients with oligometastatic eGFR driver mutations. At #WCLC19 Dr Li Zhang 🇨🇳presents in n=61 a doubling of PFS outcomes with addition of SABR #lcsm#RadOnc
@cristobalsoria Que risa cuanta estupidez junta. Pero debe ser un orgullo para @Cristiano que sus fallos tácticos en toda una carrera (si se le puede llamar así) se puedan ver solo en 40 segundos @cristobalsoria#retratado
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial: Journal of Clinical Oncology: Vol 0, No 0 https://t.co/JgXedTDtri